Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Haluska

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Molecular Cancer Therapeutics|October 17, 2013
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growthMarc A Becker, Thahir Farzan, Sean C Harrington, et al.
Neoplasia (New York, N.Y.)|June 29, 2017
Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived XenograftsKristina A Butler, Xiaonan Hou, Marc A Becker, et al.
Cancer Chemotherapy and Pharmacology|August 4, 2009
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaPaul Haluska, Frank Worden, David Olmos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2012
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumorsMarc A Becker, Xiaonan Hou, Sean C Harrington, et al.
Investigational New Drugs|September 2, 2011
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumorsAlan H Bryce, Ravi Rao, Jann Sarkaria, et al.
Scientific Reports|April 21, 2019
Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenograftsYuanhang Liu, Pritha Chanana, Jaime I Davila, et al.
Cancer Research|November 2, 2011
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancerXiaonan Hou, Fei Huang, Luciana F Macedo, et al.
Cancer|March 13, 2014
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled studyAlexis D Leal, Rui Qin, Pamela J Atherton, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Molecular Cancer Therapeutics|October 17, 2013
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growthMarc A Becker, Thahir Farzan, Sean C Harrington, et al.
Neoplasia (New York, N.Y.)|June 29, 2017
Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived XenograftsKristina A Butler, Xiaonan Hou, Marc A Becker, et al.
Cancer Chemotherapy and Pharmacology|August 4, 2009
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaPaul Haluska, Frank Worden, David Olmos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2012
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumorsMarc A Becker, Xiaonan Hou, Sean C Harrington, et al.
Investigational New Drugs|September 2, 2011
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumorsAlan H Bryce, Ravi Rao, Jann Sarkaria, et al.
Scientific Reports|April 21, 2019
Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenograftsYuanhang Liu, Pritha Chanana, Jaime I Davila, et al.
Cancer Research|November 2, 2011
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancerXiaonan Hou, Fei Huang, Luciana F Macedo, et al.
Cancer|March 13, 2014
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled studyAlexis D Leal, Rui Qin, Pamela J Atherton, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.
Pageof 7